Kampanjeplan RenovoRx, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Цена ао |
1.3 |
EBITDA |
-0.0038 |
P/BV |
2.82 |
EV/EBITDA |
-2.69 |
ISIN |
US75989R1077 |
Число акций ао |
0.01029 млрд |
Сайт |
https://renovorx.com
|
Валюта |
usd |
IPO date |
2021-08-26 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Prisendring per dag: |
-0.99% (1) |
Prisendring per uke: |
+0.0101% (0.99) |
Prisendring per måned: |
-6.59% (1.06) |
Prisendring over 3 måneder: |
-16.8% (1.19) |
Prisendring over seks måneder: |
-15.38% (1.17) |
Prisendring per år: |
-7.47% (1.07) |
Prisendring over 3 år: |
-83.25% (5.91) |
Prisendring siden begynnelsen av året: |
+52.56% (0.649) |
|
Undervurdering
Navn |
Betydning |
Karakter |
P/S |
0 |
0 |
P/BV |
-3.94 |
0 |
P/E |
0 |
0 |
EV/EBITDA |
-0.9355 |
0 |
Total: |
|
2.5 |
|
Effektivitet
Navn |
Betydning |
Karakter |
ROA, % |
-697.95 |
0 |
ROE, % |
341.07 |
10 |
Total: |
|
3.33 |
|
|
Utbytte
Navn |
Betydning |
Karakter |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0 |
|
Plikt
Navn |
Betydning |
Karakter |
Debt/EBITDA |
0 |
10 |
Total: |
|
10 |
|
Vekstimpuls
Navn |
Betydning |
Karakter |
Lønnsomhet Revenue, % |
0 |
0 |
Lønnsomhet Ebitda, % |
199.74 |
10 |
Lønnsomhet EPS, % |
120.42 |
10 |
Total: |
|
8 |
|
Veileder |
Stillingstittel |
Betaling |
Fødselsår |
Dr. Ramtin Agah M.D. |
Founder, Chairman of Board & Chief Medical Officer |
380.04k |
1966 (58 år) |
Mr. Shaun R. Bagai |
CEO, Secretary & Director |
717.75k |
1977 (47 år) |
Ms. Leesa Gentry |
Chief Clinical Officer |
N/A |
1970 (54 år) |
Mr. Ronald B. Kocak CPA, CGMA |
VP, Controller & Principal Accounting Officer |
|
1957 (67 år) |
Mr. Ryan Witt |
Senior VP and Head of Corporate Strategy & Partnerships |
|
|